AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Posted by Francis Steltz on Sep 28th, 2026

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $79.15.

ANAB has been the subject of several recent analyst reports. TD Cowen cut their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Wall Street Zen raised AnaptysBio from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright restated a “buy” rating and issued a $95.00 price objective on shares of AnaptysBio in a research report on Tuesday, September 22nd. Finally, Wolfe Research restated an “outperform” rating and issued a $78.00 price objective on shares of AnaptysBio in a research report on Monday, August 31st.

Get Our Latest Research Report on ANAB

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $51.00 on Wednesday. The company has a market capitalization of $1.52 billion, a PE ratio of 9.50 and a beta of 0.71. The company’s fifty day moving average price is $55.38 and its 200 day moving average price is $59.08. AnaptysBio has a 1 year low of $13.86 and a 1 year high of $72.36.

AnaptysBio (NASDAQ:ANAB – Get Free Report) last issued its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The business had revenue of $27.49 million during the quarter, compared to the consensus estimate of $14.06 million. During the same quarter in the prior year, the firm posted ($1.30) earnings per share. On average, equities analysts expect that AnaptysBio will post -1.48 EPS for the current year.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. First Light Asset Management LLC lifted its holdings in AnaptysBio by 2.9% during the second quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock valued at $39,285,000 after purchasing an additional 16,573 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of AnaptysBio by 21.2% during the second quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock worth $21,900,000 after purchasing an additional 56,743 shares in the last quarter. Arizona State Retirement System increased its stake in shares of AnaptysBio by 13.5% during the second quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 518 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of AnaptysBio during the 2nd quarter worth about $1,164,000. Finally, Irenic Capital Management LP acquired a new position in shares of AnaptysBio during the 2nd quarter worth about $4,755,000.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.